Summary
Global Markets Direct’s, ‘Major Depressive Disorder - Pipeline Review, H1 2016’, provides an overview of the Major Depressive Disorder pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Major Depressive Disorder
- The report reviews pipeline therapeutics for Major Depressive Disorder by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Major Depressive Disorder therapeutics and enlists all their major and minor projects
- The report assesses Major Depressive Disorder therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Major Depressive Disorder
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Major Depressive Disorder
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Major Depressive Disorder pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Aequus Pharmaceuticals Inc.
Alkermes Plc
Allergan Plc
Angelini Group
Azevan Pharmaceuticals, Inc.
BioCrea GmbH
Bristol-Myers Squibb Company
Cerecor Inc.
e-Therapeutics Plc
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
H. Lundbeck A/S
Hua Medicine Ltd.
Intra-Cellular Therapies, Inc.
Johnson & Johnson
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Luye Pharma Group Ltd.
Mapreg S.A.S.
Methylation Sciences Inc.
miCure Therapeutics Ltd.
Mitsubishi Tanabe Pharma Corporation
Neuralstem, Inc.
nLife Therapeutics, S.L.
Otsuka Holdings Co., Ltd.
Pherin Pharmaceuticals, Inc.
Reviva Pharmaceuticals Inc.
Richter Gedeon Nyrt.
Saniona AB
Sumitomo Dainippon Pharma Co., Ltd.
Suven Life Sciences Ltd.
Takeda Pharmaceutical Company Limited
TRImaran Pharma, Inc.
Turing Pharmaceuticals AG
VistaGen Therapeutics , Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Major Depressive Disorder Overview 8
Therapeutics Development 9
Pipeline Products for Major Depressive Disorder – Overview 9
Pipeline Products for Major Depressive Disorder – Comparative Analysis 10
Major Depressive Disorder – Therapeutics under Development by Companies 11
Major Depressive Disorder – Therapeutics under Investigation by Universities/Institutes 13
Major Depressive Disorder – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Major Depressive Disorder – Products under Development by Companies 17
Major Depressive Disorder – Products under Investigation by Universities/Institutes 20
Major Depressive Disorder – Companies Involved in Therapeutics Development 21
Aequus Pharmaceuticals Inc. 21
Alkermes Plc 22
Allergan Plc 23
Angelini Group 24
Azevan Pharmaceuticals, Inc. 25
BioCrea GmbH 26
Bristol-Myers Squibb Company 27
Cerecor Inc. 28
e-Therapeutics Plc 29
Eli Lilly and Company 30
F. Hoffmann-La Roche Ltd. 31
GlaxoSmithKline Plc 32
H. Lundbeck A/S 33
Hua Medicine Ltd. 34
Intra-Cellular Therapies, Inc. 35
Johnson & Johnson 36
Lead Discovery Center GmbH 37
Les Laboratoires Servier SAS 38
Luye Pharma Group Ltd. 39
Mapreg S.A.S. 40
Methylation Sciences Inc. 41
miCure Therapeutics Ltd. 42
Mitsubishi Tanabe Pharma Corporation 43
Neuralstem, Inc. 44
nLife Therapeutics, S.L. 45
Otsuka Holdings Co., Ltd. 46
Pherin Pharmaceuticals, Inc. 47
Reviva Pharmaceuticals Inc. 48
Richter Gedeon Nyrt. 49
Saniona AB 50
Sumitomo Dainippon Pharma Co., Ltd. 51
Suven Life Sciences Ltd. 52
Takeda Pharmaceutical Company Limited 53
TRImaran Pharma, Inc. 54
Turing Pharmaceuticals AG 55
VistaGen Therapeutics , Inc. 56
Major Depressive Disorder – Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Target 59
Assessment by Mechanism of Action 62
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
(aripiprazole + sertraline) - Drug Profile 69
(buprenorphine hydrochloride + samidorphan l-malate) - Drug Profile 70
AAD-2004 - Drug Profile 72
ALKS-7119 - Drug Profile 73
AN-788 - Drug Profile 74
aripiprazole - Drug Profile 75
AV-101 - Drug Profile 76
AVP-786 - Drug Profile 78
basimglurant - Drug Profile 80
BLI-1005 - Drug Profile 82
brexpiprazole - Drug Profile 83
bupropion hydrochloride ER - Drug Profile 86
cariprazine - Drug Profile 87
CB-2202 - Drug Profile 90
CERC-301 - Drug Profile 91
CERC-501 - Drug Profile 92
D-473 - Drug Profile 93
edivoxetine hydrochloride - Drug Profile 94
esketamine hydrochloride - Drug Profile 96
gepirone hydrochloride ER - Drug Profile 99
ITI-007 - Drug Profile 101
JNJ-42847922 - Drug Profile 104
ketamine hydrochloride - Drug Profile 106
lurasidone hydrochloride - Drug Profile 107
LY-03005 - Drug Profile 110
MAP-4343 - Drug Profile 112
MIN-117 - Drug Profile 113
miR-135 - Drug Profile 114
MSI-195 - Drug Profile 115
NLF-NEU - Drug Profile 116
NP-11948 - Drug Profile 118
NRX-1074 - Drug Profile 119
NSI-189 - Drug Profile 120
onabotulinumtoxin A - Drug Profile 122
PH-10 - Drug Profile 125
rapastinel - Drug Profile 126
RP-5063 - Drug Profile 128
S-47445 - Drug Profile 129
sirukumab - Drug Profile 130
Small Molecule to Inhibit FKBP51 for Anxiety and Major Depressive Disorder - Drug Profile 133
Small Molecule to Target SLC6A15 for Major Depressive Disorder - Drug Profile 134
Small Molecules to Antagonize mGLUR5 for Central Nervous System Disorders - Drug Profile 135
Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile 136
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System - Drug Profile 137
SNA-1 - Drug Profile 138
SRX-246 - Drug Profile 139
SUVN-911 - Drug Profile 141
TAK-653 - Drug Profile 142
tramadol hydrochloride - Drug Profile 143
trazodone hydrochloride - Drug Profile 144
vortioxetine hydrobromide - Drug Profile 145
VU-0431316 - Drug Profile 148
Major Depressive Disorder – Recent Pipeline Updates 149
Major Depressive Disorder - Dormant Projects 201
Major Depressive Disorder – Discontinued Products 208
Major Depressive Disorder – Product Development Milestones 211
Featured News & Press Releases 211
Appendix 219
Methodology 219
Coverage 219
Secondary Research 219
Primary Research 219
Expert Panel Validation 219
Contact Us 219
Disclaimer 220
List of Tables
Number of Products under Development for Major Depressive Disorder, H1 2016 13
Number of Products under Development for Major Depressive Disorder – Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Products under Development by Companies, H1 2016 21
Products under Development by Companies, H1 2016 (Contd..1) 22
Products under Development by Companies, H1 2016 (Contd..2) 23
Products under Investigation by Universities/Institutes, H1 2016 24
Major Depressive Disorder – Pipeline by Aequus Pharmaceuticals Inc., H1 2016 25
Major Depressive Disorder – Pipeline by Alkermes Plc, H1 2016 26
Major Depressive Disorder – Pipeline by Allergan Plc, H1 2016 27
Major Depressive Disorder – Pipeline by Angelini Group, H1 2016 28
Major Depressive Disorder – Pipeline by Azevan Pharmaceuticals, Inc., H1 2016 29
Major Depressive Disorder – Pipeline by BioCrea GmbH, H1 2016 30
Major Depressive Disorder – Pipeline by Bristol-Myers Squibb Company, H1 2016 31
Major Depressive Disorder – Pipeline by Cerecor Inc., H1 2016 32
Major Depressive Disorder – Pipeline by e-Therapeutics Plc, H1 2016 33
Major Depressive Disorder – Pipeline by Eli Lilly and Company, H1 2016 34
Major Depressive Disorder – Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 35
Major Depressive Disorder – Pipeline by GlaxoSmithKline Plc, H1 2016 36
Major Depressive Disorder – Pipeline by H. Lundbeck A/S, H1 2016 37
Major Depressive Disorder – Pipeline by Hua Medicine Ltd., H1 2016 38
Major Depressive Disorder – Pipeline by Intra-Cellular Therapies, Inc., H1 2016 39
Major Depressive Disorder – Pipeline by Johnson & Johnson, H1 2016 40
Major Depressive Disorder – Pipeline by Lead Discovery Center GmbH, H1 2016 41
Major Depressive Disorder – Pipeline by Les Laboratoires Servier SAS, H1 2016 42
Major Depressive Disorder – Pipeline by Luye Pharma Group Ltd., H1 2016 43
Major Depressive Disorder – Pipeline by Mapreg S.A.S., H1 2016 44
Major Depressive Disorder – Pipeline by Methylation Sciences Inc., H1 2016 45
Major Depressive Disorder – Pipeline by miCure Therapeutics Ltd., H1 2016 46
Major Depressive Disorder – Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 47
Major Depressive Disorder – Pipeline by Neuralstem, Inc., H1 2016 48
Major Depressive Disorder – Pipeline by nLife Therapeutics, S.L., H1 2016 49
Major Depressive Disorder – Pipeline by Otsuka Holdings Co., Ltd., H1 2016 50
Major Depressive Disorder – Pipeline by Pherin Pharmaceuticals, Inc., H1 2016 51
Major Depressive Disorder – Pipeline by Reviva Pharmaceuticals Inc., H1 2016 52
Major Depressive Disorder – Pipeline by Richter Gedeon Nyrt., H1 2016 53
Major Depressive Disorder – Pipeline by Saniona AB, H1 2016 54
Major Depressive Disorder – Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 55
Major Depressive Disorder – Pipeline by Suven Life Sciences Ltd., H1 2016 56
Major Depressive Disorder – Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 57
Major Depressive Disorder – Pipeline by TRImaran Pharma, Inc., H1 2016 58
Major Depressive Disorder – Pipeline by Turing Pharmaceuticals AG , H1 2016 59
Major Depressive Disorder – Pipeline by VistaGen Therapeutics , Inc., H1 2016 60
Assessment by Monotherapy Products, H1 2016 61
Assessment by Combination Products, H1 2016 62
Number of Products by Stage and Target, H1 2016 64
Number of Products by Stage and Mechanism of Action, H1 2016 67
Number of Products by Stage and Route of Administration, H1 2016 70
Number of Products by Stage and Molecule Type, H1 2016 72
Major Depressive Disorder Therapeutics – Recent Pipeline Updates, H1 2016 153
Major Depressive Disorder – Dormant Projects, H1 2016 205
Major Depressive Disorder – Dormant Projects (Contd..1), H1 2016 206
Major Depressive Disorder – Dormant Projects (Contd..2), H1 2016 207
Major Depressive Disorder – Dormant Projects (Contd..3), H1 2016 208
Major Depressive Disorder – Dormant Projects (Contd..4), H1 2016 209
Major Depressive Disorder – Dormant Projects (Contd..5), H1 2016 210
Major Depressive Disorder – Dormant Projects (Contd..6), H1 2016 211
Major Depressive Disorder – Discontinued Products, H1 2016 212
Major Depressive Disorder – Discontinued Products (Contd..1), H1 2016 213
Major Depressive Disorder – Discontinued Products (Contd..2), H1 2016 214
List of Figures
Number of Products under Development for Major Depressive Disorder, H1 2016 13
Number of Products under Development for Major Depressive Disorder – Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Products, H1 2016 20
Assessment by Monotherapy Products, H1 2016 61
Number of Products by Top 10 Targets, H1 2016 63
Number of Products by Stage and Top 10 Targets, H1 2016 63
Number of Products by Top 10 Mechanism of Actions, H1 2016 66
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 66
Number of Products by Routes of Administration, H1 2016 69
Number of Products by Stage and Routes of Administration, H1 2016 69
Number of Products by Molecule Types, H1 2016 71
Number of Products by Stage and Molecule Types, H1 2016 71
